Antibe Therapeutics Inc(Pre-Merger) ATBPF

Updates from Dan

[lpthegreat]

This is an email thread with Dan directly from early Novemeber. Optimistic.

Hi Dan - I hope all is well.

 

I am wondering if there are any updates you can share with a shareholder. I believe in what you are setting up. We are weathering the storm right now.

 

Best,

LP
---------------------------------------------------------------------------------------------------------------------

Hi LP,

…appreciate this…it looks quiet, but now that we are a P3 company, things are ‘larger’ and more methodical.

We have 9 toxicology studies underway at the moment, and will start another one this week (all things that are needed prior to a P3 start…long range tox; reproductive tox and phototox).

We have started our outreach to large Pharma, as well as to the US investment community. And we will soon graduate to the senior TSX. 

A lot going on!

Cheers,

Dan

[MrMugsy]

Thanks for sharing IPthegreat.

[IrishCanuck]

Most in vivo toxicology studies don't take long and we have had six months pass since Phase 2 was released. I hope they initiated long term toxicology for carcinogenesis long before June or else we'll be waiting a few years... but considering Otenaproxesul is based on compounds naturally produced in the body for cell signalling you could very quickly reduce that parameter timeframe with

[Pragmatist]

I suspect the CEO was a tad imprecise  in his email.  From the latest MD&A regarding current studies:     "They are being conducted in tranches to enable a timely start to Phase III clinical trials. Short range studies are expected to conclude in calendar Q2 2021, enabling the commencement of the 12-week Phase III efficacy trials. Long range studies are

[MrMugsy]

I do recall Dan saying the studies will finish at different times, going out to the end of 2021.  I assumed the only study requred for enabling (FDA meeting and the go-head from them) was the one due in Q4 2020 - toxicity study.  Any chance that's correct?  With the others to follow and to be provided to FDA as they are completed?

[Pragmatist]

I don't recall him mentioning any specific study.  I was under the impression (perhaps wrongly) that the upcoming FDA meeting was more of a consultatory meeting prior to submitting an IND, almost a repeat of the pre-IND meeting but with all Phase 2B results in hand. The company, after all, is moving from trials conducted under Canadian Health authorities to those under the FDA.  

[Pragmatist]

Further to my last post, I suspect that ATE will submit its IND before the more substantive end-phase 2 meeting. This would have been  done prior to PH 1 clinical trials had ATE conducted its prior development under the FDA.